IAN MISCAMPBELL (Non Executive Chair)
Ian has served as Chief Finance Officer and as Chief Operating Officer in a number of publicly quoted and privately owned healthcare and drug development companies, including Reneuron, KS Biomedix, Microscience, Oxford Immunotec, William Ransom and York Pharma. He was responsible for numerous M&A and licensing transactions and has completed multiple financing and re-financing transactions, successfully raising in excess of £100m in equity, debt and grant finance.
Having worked as Finance Director in a healthcare fund management business, Ian left in 2010 to establish Sixth Element Capital, where he is Managing Partner. Ian was appointed a Fellow of the Institute of Chartered Accountants in England and Wales in 2011.
STEPHAN CHRISTGAU (Non-Executive Director)
Stephan joined Novo A/S in September 2007 as Investment Director of Novo Seeds. He obtained his MSc degree from the Technical University of Denmark in 1988 and his PhD degree in 1992 from the Technical University of Denmark, for a project in diabetes immunology, conducted at Hagedorn Research Institute and University of California, San Francisco.
Prior to joining Novo Seeds, Stephan was Executive Vice President and Chief Operating Officer at Osteologix. Previously he has worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S. Stephan serves on the Board of Directors of Acesion Pharma, Adenium Biotech ApS, Forendo Pharma OY, Galecto Biotech AB, Heparegenix GmbH, IO Biotech, Lysogene SA and NMD Pharma. He also serves as chairman for VentureCup, a non-profit entrepreneurship organization.
MARK KRUL (Non-Executive Director)
Mark has been involved in anticancer drug development since 1993 and has a background in molecular biology and immunology. Before founding Aglaia BioMedical Ventures in 2003 he was Program Director of the NDDO Research Foundation. He held several positions at NDDO Oncology BV (formerly the EORTC New Drug Development Office) with respect to oncology drug development strategies (1997-2002). From 1993 till 1997 Mark has been Research Manager of the European Cancer Center and headed the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection from 1989 till 1993.
HAKAN GOKER (Non-Executive Director)
Hakan is a senior investment director at Merck Ventures, corporate venture arm of the Biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Hakan joined Merck Ventures in 2013 and previously was investing as a partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and strategy of multiple biotechnology companies globally including Asceneuron (CH), Orphazyme (DK), Nimbus Discovery (US), F Star (NL), Bicycle Therapeutics (UK) and Nitec now Horizon Pharma (CH/US). Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is currently a board member of Asceneuron, Artios Pharma, Forendo, Raze Therapeutics, Tocopherx, Synaffix, and Storm Therapeutics.
STEVEN POWELL (Executive Director)
Steven graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen. He has 30 years operational and investment experience in pharmaceutical and healthcare R&D. Steven has held four CEO roles, two in public companies, and has led or participated in over 50 corporate transactions.